Modulation of S1P in the Treatment of Autoimmune Diseases
We recommend
Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It is approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and moderate to severe ulcerative colitis (UC) and continues to undergo intensive clinical research. The DAYBREAK open-label, single-arm study for participants with RRMS from previous trials with ozanimod was scheduled to be completed by January 2023, and its final results can therefore be expected soon. The following article presents the interim analysis results…
Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
The immunosuppressive ozanimod was approved for the treatment of ulcerative colitis (UC) based on…
Efficacy and Safety of Ozanimod in the Treatment of Relapsing-Remitting MS
The sphingosine-1-phosphate receptor (S1PR) modulator ozanimod has recently been approved for the…
Articles on this topic
Ozanimod Expands Treatment Options for Ulcerative Colitis in Adult Patients
As a review article published last year in the journal Drugs suggests, ozanimod is an…
Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis − True North Study Results
Ozanimod is a selective modulator of the sphingosine-1-phosphate receptor (S1PR) approved for…
Invitation to ZEPOSIA STAND ALONE MEETING
On behalf of Bristol Myers Squibb, we warmly invite you to the Zeposia Stand Alone Meeting, which...
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- Ozanimod Expands Treatment Options for Ulcerative Colitis in Adult Patients
- Efficacy and Safety of Ozanimod in the Treatment of Relapsing-Remitting MS
- Invitation to ZEPOSIA STAND ALONE MEETING
- Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
- Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis − True North Study Results
- Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
Journal on this topic
Related topic
Interesting links